Monday, 17 December 2018

Australia gives its nod to Trastuzumab Biosimilar

09 August 2018 | News

The trastuzumab biosimilar will join 2 other anticancer biosimilars on the list of TAG’s approved biosimilars.

Image credit- mlwindaction.org

Image credit- mlwindaction.org

Australia’s Therapeutic Goods Administration (TAG) has approved Celltrion’s Herzuma, the country’s first biosimilar trastuzumab.

While Celltrion is in discussions with affiliates concerning distribution channels for the drug approved to treat HER2-positive cancers, it has not yet decided on a launch date.

The trastuzumab biosimilar will join 2 other anticancer biosimilars on the list of TAG’s approved biosimilars—2 rituximab products referencing Rituxan have been approved.

Other biozimilars authorized in Australia include adalimumab, etanercept, infliximab, filgrastim, epoetin alfa, insulin glargine, and follitropin alfa. Unlike the United States, Australia addresses follow-on insulins and human follicle-stimulating hormones as biosimilars.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Is digital transformation changing APAC’s healthcare landscape?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls